tradingkey.logo

10X Genomics Inc

TXG
查看詳細走勢圖
20.350USD
+1.060+5.50%
交易中 美東報價延遲15分鐘
2.58B總市值
虧損本益比TTM

10X Genomics Inc

20.350
+1.060+5.50%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+5.50%

5天

+24.77%

1月

+16.49%

6月

+66.12%

今年開始到現在

+24.77%

1年

+28.55%

查看詳細走勢圖

TradingKey 10X Genomics Inc股票評分

單位: USD 更新時間: 2026-01-08

操作建議

10X Genomics Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名40/208位。機構持股佔比非常高,近一月多位分析師給出公司評級為持有。最高目標價為17.27。中期看,股價處於上升通道。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

10X Genomics Inc評分

相關信息

行業排名
40 / 208
全市場排名
112 / 4563
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看空

10X Genomics Inc亮點

亮點風險
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
業績高增長
公司營業收入穩步增長,連續3年增長18.28%
估值低估
公司最新PE估值-30.93,處於3年歷史低位
機構減倉
最新機構持股125.94M股,環比減少11.00%
Hotchkis & Wiley持倉
明星投資者Hotchkis & Wiley持倉,最新持倉2.42K股
活躍度降低
近期活躍度降低,過去20天平均換手率0.35

分析師目標

基於 18 分析師
持有
評級
17.267
目標均價
-5.75%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

10X Genomics Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

10X Genomics Inc簡介

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
公司代碼TXG
公司10X Genomics Inc
CEOSaxonov (Serge Wilson)
網址https://www.10xgenomics.com/

常見問題

10X Genomics Inc(TXG)的當前股價是多少?

10X Genomics Inc(TXG)的當前股價是 20.350。

10X Genomics Inc 的股票代碼是什麼?

10X Genomics Inc的股票代碼是TXG。

10X Genomics Inc股票的52週最高點是多少?

10X Genomics Inc股票的52週最高點是20.340。

10X Genomics Inc股票的52週最低點是多少?

10X Genomics Inc股票的52週最低點是6.780。

10X Genomics Inc的市值是多少?

10X Genomics Inc的市值是2.58B。

10X Genomics Inc的淨利潤是多少?

10X Genomics Inc的淨利潤為-182.63M。

現在10X Genomics Inc(TXG)的股票是買入、持有還是賣出?

根據分析師評級,10X Genomics Inc(TXG)的總體評級為持有,目標價格為17.267。

10X Genomics Inc(TXG)股票的每股收益(EPS TTM)是多少

10X Genomics Inc(TXG)股票的每股收益(EPS TTM)是-0.624。
KeyAI